PHIBRO ANIMAL HEALTH CORP PAHC Financial Statement Data


2025 Q2

Submissions

Field Row 1
adsh 0001558370-25-006746
cik 1069899
name PHIBRO ANIMAL HEALTH CORP
sic 2834
countryba US
stprba NJ
cityba TEANECK
zipba 07666
bas1 GLENPOINTE CENTRE EAST, 3RD FLOOR
bas2 300 FRANK W. BURR BLVD., SUITE 21
baph 201-329-7300
countryma US
stprma NJ
cityma TEANECK
zipma 07666
mas1 GLENPOINTE CENTRE EAST, 3RD FLOOR
mas2 300 FRANK W. BURR BLVD., SUITE 21
countryinc US
stprinc DE
ein 131840497
former PHILIPP BROTHERS CHEMICALS INC
changed 19980908
afs 2-ACC
wksi 0
fye 0630
form 10-Q
period 20250331
fy 2025
fp Q3
filed 20250507
accepted 2025-05-07 16:17:00.0
prevrpt 0
detail 1
instance pahc-20250331x10q_htm.xml
nciks 1
aciks

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
cik Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings.
name Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date.
sic Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business.
countryba The ISO 3166-1 country of the registrant's business address.
stprba The state or province of the registrant’s business address, if field countryba is US or CA.
cityba The city of the registrant's business address.
zipba The zip code of the registrant’s business address.
bas1 The first line of the street of the registrant’s business address.
bas2 The second line of the street of the registrant’s business address.
baph The phone number of the registrant’s business address.
countryma The ISO 3166-1 country of the registrant's mailing address.
stprma The state or province of the registrant’s mailing address, if field countryma is US or CA.
cityma The city of the registrant's mailing address.
zipma The zip code of the registrant’s mailing address.
mas1 The first line of the street of the registrant’s mailing address.
mas2 The second line of the street of the registrant’s mailing address.
countryinc The ISO 3166-1 country of incorporation for the registrant.
stprinc The state or province of incorporation for the registrant, if countryinc is US or CA.
ein Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States.
former Most recent former name of the registrant, if any.
changed Date of change from the former name, if any.
afs Filer status with the SEC at the time of submission:
1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned.
wksi Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement.
fye Fiscal Year End Date, rounded to nearest month-end.
form The submission type of the registrant’s filing.
period Balance Sheet Date, rounded to nearest month-end.
fy Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8).
fp Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year.
filed The date of the registrant’s filing with the Commission.
accepted The acceptance date and time of the registrant’s filing with the Commission.
prevrpt Previous Report – TRUE indicates that the submission information was subsequently amended.
detail TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount).
instance The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol.
nciks Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing.
aciks Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information.

Numbers

adsh ddate tag value uom qtrs version segments coreg footnote
0001558370-25-006746 20230930 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 81000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20230930 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 81000.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001558370-25-006746 20240630 Assets 982184000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20250331 Assets 78922000.0000 USD 0 us-gaap/2024 Business Segments= Mineral Nutrition; Consolidation Items= Operating Segments;
0001558370-25-006746 20250331 Assets 51768000.0000 USD 0 us-gaap/2024 Business Segments= Performance Products; Consolidation Items= Operating Segments;
0001558370-25-006746 20250331 Assets Current 776018000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20240331 Common Stock Dividends Per Share Declared 0.1200 USD 1 us-gaap/2024
0001558370-25-006746 20240630 Common Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024 Class Of Stock= Common Class B;
0001558370-25-006746 20250331 Common Stock Shares Authorized 300000000.0000 shares 0 us-gaap/2024 Class Of Stock= Common Class A;
0001558370-25-006746 20230930 Common Stock Shares Issued 40503608.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0001558370-25-006746 20231231 Common Stock Shares Issued 40503608.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0001558370-25-006746 20230930 Comprehensive Income Net Of Tax -4661000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20231231 Comprehensive Income Net Of Tax 2515000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20250331 Comprehensive Income Net Of Tax 20880000.0000 USD 1 us-gaap/2024 Equity Components= Retained Earnings;
0001558370-25-006746 20240331 Cost Of Goods And Services Sold 518573000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Cost Of Goods And Services Sold 243257000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20250331 Cost Of Goods And Services Sold 627585000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240331 Depreciation Depletion And Amortization 26977000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240331 Depreciation Depletion And Amortization 1907000.0000 USD 3 us-gaap/2024 Business Segments= Mineral Nutrition; Consolidation Items= Operating Segments;
0001558370-25-006746 20240331 Depreciation Depletion And Amortization 25590000.0000 USD 3 us-gaap/2024 Consolidation Items= Operating Segments;
0001558370-25-006746 20250331 Depreciation Depletion And Amortization 1555000.0000 USD 3 us-gaap/2024 Business Segments= Mineral Nutrition; Consolidation Items= Operating Segments;
0001558370-25-006746 20231231 Dividends Common Stock Cash 4861000.0000 USD 1 us-gaap/2024 Equity Components= Retained Earnings;
0001558370-25-006746 20240331 Dividends Common Stock Cash 4860000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20240331 Earnings Per Share Basic 0.2100 USD 1 us-gaap/2024
0001558370-25-006746 20240331 Earnings Per Share Diluted 0.2100 USD 1 us-gaap/2024
0001558370-25-006746 20250331 Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents -2357000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240331 Foreign Currency Transaction Gain Loss Before Tax -2427000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20240331 Increase Decrease In Other Noncurrent Assets -624000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240630 Liabilities 725543000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20240331 Net Income Loss 8405000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20240331 Net Income Loss 1664000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240331 Operating Income Loss 34899000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240630 Other Assets Current 51021000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20250331 Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Before Tax Parent 49000.0000 USD 3 us-gaap/2024 Derivative Instrument Risk= Foreign Exchange Option;
0001558370-25-006746 20250331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent -7642000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240630 Other Liabilities Noncurrent 63106000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20240331 Other Noncash Income Expense -3865000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Payments Of Dividends Common Stock 14585000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Payments To Acquire Businesses Net Of Cash Acquired 291878000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240331 Payments To Acquire Short Term Investments 65523000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Preferred Stock Shares Outstanding 0.0000 shares 0 us-gaap/2024
0001558370-25-006746 20240331 Proceeds From Insurance Premium Financing Financing Activities 2694000.0000 USD 3 0001558370-25-006746
0001558370-25-006746 20240331 Profit Loss 1664000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240331 Revenue From Contract With Customer Excluding Assessed Tax 17081000.0000 USD 1 us-gaap/2024 Geographical= Asia Pacific;
0001558370-25-006746 20240331 Revenue From Contract With Customer Excluding Assessed Tax 181333000.0000 USD 1 us-gaap/2024 Product Or Service= Animal Health;
0001558370-25-006746 20240331 Revenue From Contract With Customer Excluding Assessed Tax 108216000.0000 USD 1 us-gaap/2024 Product Or Service= Medicated Feed Additives And Others;
0001558370-25-006746 20240331 Revenue From Contract With Customer Excluding Assessed Tax 47947000.0000 USD 3 us-gaap/2024 Business Segments= Performance Products;
0001558370-25-006746 20250331 Revenue From Contract With Customer Excluding Assessed Tax 58114000.0000 USD 3 us-gaap/2024 Business Segments= Performance Products;
0001558370-25-006746 20250331 Revenue From Contract With Customer Excluding Assessed Tax 439827000.0000 USD 3 us-gaap/2024 Product Or Service= Medicated Feed Additives And Others;
0001558370-25-006746 20250331 Revenue From Contract With Customer Excluding Assessed Tax 189086000.0000 USD 3 us-gaap/2024 Product Or Service= Mineral Nutrition;
0001558370-25-006746 20250331 Revenue From Contract With Customer Excluding Assessed Tax 98583000.0000 USD 3 us-gaap/2024 Product Or Service= Vaccines;
0001558370-25-006746 20250331 Selling General And Administrative Expense 213186000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Share Based Compensation 179000.0000 USD 1 us-gaap/2024 Consolidation Items= Operating Segments;
0001558370-25-006746 20250331 Share Based Compensation 538000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Stockholders Equity 265992000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20240930 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 258527000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20241231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 136637000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001558370-25-006746 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -131169000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001558370-25-006746 20250331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 179000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20240630 Assets 802357000.0000 USD 0 us-gaap/2024 Consolidation Items= Operating Segments;
0001558370-25-006746 20250331 Assets 144692000.0000 USD 0 us-gaap/2024 Consolidation Items= Corporate Non Segment;
0001558370-25-006746 20240630 Assets Current 600997000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20230930 Common Stock Dividends Per Share Declared 0.1200 USD 1 us-gaap/2024
0001558370-25-006746 20230930 Comprehensive Income Net Of Tax -8015000.0000 USD 1 us-gaap/2024 Equity Components= Retained Earnings;
0001558370-25-006746 20240930 Comprehensive Income Net Of Tax -408000.0000 USD 1 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001558370-25-006746 20241231 Comprehensive Income Net Of Tax -7045000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20250331 Comprehensive Income Net Of Tax 2996000.0000 USD 1 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001558370-25-006746 20250331 Comprehensive Income Net Of Tax 23398000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240331 Depreciation Depletion And Amortization 1291000.0000 USD 3 us-gaap/2024 Business Segments= Performance Products; Consolidation Items= Operating Segments;
0001558370-25-006746 20250331 Depreciation Depletion And Amortization 902000.0000 USD 3 us-gaap/2024 Business Segments= Performance Products; Consolidation Items= Operating Segments;
0001558370-25-006746 20230930 Dividends Common Stock Cash 4860000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20230930 Dividends Common Stock Cash 4860000.0000 USD 1 us-gaap/2024 Equity Components= Retained Earnings;
0001558370-25-006746 20240331 Earnings Per Share Basic 0.0400 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Earnings Per Share Diluted 0.7600 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Finite Lived Intangible Assets Net 37766000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20250331 Foreign Currency Transaction Gain Loss Unrealized -5683000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Gross Profit 104568000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20240331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest 4508000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest 44146000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240331 Income Tax Expense Benefit 4517000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20240331 Increase Decrease In Inventories 5891000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Increase Decrease In Other Noncurrent Assets -3809000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240331 Interest Income Expense Nonoperating Net -13798000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Liabilities 1051268000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20250331 Net Income Loss 31040000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Operating Income Loss 33515000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20240331 Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent -3045000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20240331 Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Before Tax Parent 35000.0000 USD 3 us-gaap/2024 Derivative Instrument Risk= Foreign Exchange Option;
0001558370-25-006746 20240331 Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Net Unamortized Gain Loss Arising During Period Before Tax 837000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240331 Other Comprehensive Income Loss Tax Portion Attributable To Parent1 -357000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20240331 Other Comprehensive Income Loss Tax Portion Attributable To Parent1 711000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Payments For Proceeds From Other Investing Activities -1375000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240630 Preferred Stock Shares Authorized 16000000.0000 shares 0 us-gaap/2024
0001558370-25-006746 20250331 Preferred Stock Shares Authorized 16000000.0000 shares 0 us-gaap/2024
0001558370-25-006746 20250331 Profit Loss 31040000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240331 Revenue From Contract With Customer Excluding Assessed Tax 304261000.0000 USD 3 us-gaap/2024 Product Or Service= Medicated Feed Additives And Others;
0001558370-25-006746 20250331 Revenue From Contract With Customer Excluding Assessed Tax 70753000.0000 USD 1 us-gaap/2024 Geographical= Latin America And Canada;
0001558370-25-006746 20250331 Revenue From Contract With Customer Excluding Assessed Tax 209940000.0000 USD 1 us-gaap/2024 Geographical= U S;
0001558370-25-006746 20240331 Selling General And Administrative Expense 191043000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240630 Short Term Investments 44000000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20240630 Short Term Investments 0.0000 USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level3;
0001558370-25-006746 20250331 Short Term Investments 10000000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20240630 Stockholders Equity 256641000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 270094000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 247995000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001558370-25-006746 20240630 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 256641000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20240630 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -123527000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001558370-25-006746 20240630 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 136278000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001558370-25-006746 20250331 Weighted Average Number Of Diluted Shares Outstanding 40669000.0000 shares 3 us-gaap/2024
0001558370-25-006746 20250331 Accounts Payable Current 131622000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20231231 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 80000.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001558370-25-006746 20240930 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 179000.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001558370-25-006746 20241231 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 180000.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001558370-25-006746 20250331 Asset Impairment Charges 1500000.0000 USD 1 us-gaap/2024 Income Statement Location= Selling General And Administrative Expenses;
0001558370-25-006746 20250331 Asset Impairment Charges 3800000.0000 USD 3 us-gaap/2024 Income Statement Location= Cost Of Sales;
0001558370-25-006746 20240630 Assets 67088000.0000 USD 0 us-gaap/2024 Business Segments= Mineral Nutrition; Consolidation Items= Operating Segments;
0001558370-25-006746 20250331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 60354000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20240630 Commitments And Contingencies USD 0 us-gaap/2024
0001558370-25-006746 20250331 Common Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024 Class Of Stock= Common Class B;
0001558370-25-006746 20250331 Common Stock Shares Outstanding 20166034.0000 shares 0 us-gaap/2024 Class Of Stock= Common Class B;
0001558370-25-006746 20231231 Comprehensive Income Net Of Tax 1274000.0000 USD 1 us-gaap/2024 Equity Components= Retained Earnings;
0001558370-25-006746 20240331 Comprehensive Income Net Of Tax 4016000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20250331 Comprehensive Income Net Of Tax 23876000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20240331 Depreciation Depletion And Amortization 9196000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20240331 Depreciation Depletion And Amortization 432000.0000 USD 1 us-gaap/2024 Business Segments= Performance Products; Consolidation Items= Operating Segments;
0001558370-25-006746 20250331 Depreciation Depletion And Amortization 11369000.0000 USD 1 us-gaap/2024 Business Segments= Animal Health; Consolidation Items= Operating Segments;
0001558370-25-006746 20250331 Revenue From Contract With Customer Excluding Assessed Tax 102624000.0000 USD 3 us-gaap/2024 Geographical= E M E A;
0001558370-25-006746 20250331 Depreciation Depletion And Amortization 524000.0000 USD 1 us-gaap/2024 Business Segments= Mineral Nutrition; Consolidation Items= Operating Segments;
0001558370-25-006746 20250331 Depreciation Depletion And Amortization 1419000.0000 USD 3 us-gaap/2024 Consolidation Items= Corporate Non Segment;
0001558370-25-006746 20240930 Dividends Common Stock Cash 4860000.0000 USD 1 us-gaap/2024 Equity Components= Retained Earnings;
0001558370-25-006746 20240331 Earnings Per Share Diluted 0.0400 USD 3 us-gaap/2024
0001558370-25-006746 20240331 Income Tax Expense Benefit 2844000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Income Tax Expense Benefit 13106000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Increase Decrease In Accounts Payable 42936000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240331 Increase Decrease In Prepaid Deferred Expense And Other Assets -3437000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240630 Long Term Line Of Credit 176000000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20250331 Long Term Line Of Credit 92000000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20240331 Net Cash Provided By Used In Financing Activities -8555000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent 6895000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20250331 Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Before Tax Parent -5274000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20250331 Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Before Tax Parent 169000.0000 USD 1 us-gaap/2024 Derivative Instrument Risk= Foreign Exchange Option;
0001558370-25-006746 20250331 Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Before Tax Parent -5443000.0000 USD 1 us-gaap/2024 Derivative Instrument Risk= Interest Rate Swap;
0001558370-25-006746 20250331 Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Before Tax Parent -7934000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Other Comprehensive Income Loss Tax Portion Attributable To Parent1 -1927000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240331 Payments For Insurance Premium Financing Financing Activities 5353000.0000 USD 3 0001558370-25-006746
0001558370-25-006746 20250331 Payments Of Debt Issuance Costs 10377000.0000 USD 3 us-gaap/2024 Debt Instrument= Credit Agreement2024; Longterm Debt Type= Secured Debt;
0001558370-25-006746 20250331 Payments To Acquire Businesses Net Of Cash Acquired 291900000.0000 USD 3 us-gaap/2024 Business Acquisition= Zoetis Inc Medicated Feed Additive Product Portfolio;
0001558370-25-006746 20250331 Payments To Acquire Productive Assets 25151000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240630 Preferred Stock Shares Outstanding 0.0000 shares 0 us-gaap/2024
0001558370-25-006746 20250331 Proceeds From Issuance Of Other Long Term Debt 650000000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240331 Revenue From Contract With Customer Excluding Assessed Tax 159314000.0000 USD 1 us-gaap/2024 Geographical= U S;
0001558370-25-006746 20240331 Revenue From Contract With Customer Excluding Assessed Tax 64228000.0000 USD 1 us-gaap/2024 Product Or Service= Mineral Nutrition;
0001558370-25-006746 20240331 Revenue From Contract With Customer Excluding Assessed Tax 17662000.0000 USD 1 us-gaap/2024 Product Or Service= Performance Products;
0001558370-25-006746 20240331 Revenue From Contract With Customer Excluding Assessed Tax 181601000.0000 USD 3 us-gaap/2024 Business Segments= Mineral Nutrition;
0001558370-25-006746 20240331 Revenue From Contract With Customer Excluding Assessed Tax 89572000.0000 USD 3 us-gaap/2024 Geographical= E M E A;
0001558370-25-006746 20240331 Revenue From Contract With Customer Excluding Assessed Tax 177539000.0000 USD 3 us-gaap/2024 Geographical= Latin America And Canada;
0001558370-25-006746 20240331 Revenue From Contract With Customer Excluding Assessed Tax 47947000.0000 USD 3 us-gaap/2024 Product Or Service= Performance Products;
0001558370-25-006746 20250331 Revenue From Contract With Customer Excluding Assessed Tax 181645000.0000 USD 1 us-gaap/2024 Product Or Service= Medicated Feed Additives And Others;
0001558370-25-006746 20250331 Revenue From Contract With Customer Excluding Assessed Tax 22674000.0000 USD 1 us-gaap/2024 Product Or Service= Performance Products;
0001558370-25-006746 20250331 Short Term Investments 10000000.0000 USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level1;
0001558370-25-006746 20230630 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 260912000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001558370-25-006746 20231231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 4000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001558370-25-006746 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 136099000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001558370-25-006746 20240630 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 243886000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001558370-25-006746 20241231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 4000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001558370-25-006746 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 260341000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001558370-25-006746 20240331 Weighted Average Number Of Diluted Shares Outstanding 40520000.0000 shares 1 us-gaap/2024
0001558370-25-006746 20240331 Weighted Average Number Of Diluted Shares Outstanding 40509000.0000 shares 3 us-gaap/2024
0001558370-25-006746 20250331 Weighted Average Number Of Diluted Shares Outstanding 40709000.0000 shares 1 us-gaap/2024
0001558370-25-006746 20240630 Accounts Payable Current 85567000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20250331 Accrued Liabilities And Other Liabilities Current 118609000.0000 USD 0 0001558370-25-006746
0001558370-25-006746 20250331 Accumulated Other Comprehensive Income Loss Net Of Tax -131169000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20250331 Amortization Of Financing Costs 1443000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240630 Assets 179827000.0000 USD 0 us-gaap/2024 Consolidation Items= Corporate Non Segment;
0001558370-25-006746 20240630 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 70613000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20250331 Common Stock Dividends Per Share Declared 0.1200 USD 1 us-gaap/2024
0001558370-25-006746 20250331 Common Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024 Class Of Stock= Common Class A;
0001558370-25-006746 20240630 Common Stock Shares Authorized 300000000.0000 shares 0 us-gaap/2024 Class Of Stock= Common Class A;
0001558370-25-006746 20240630 Common Stock Shares Issued 20337574.0000 shares 0 us-gaap/2024 Class Of Stock= Common Class A;
0001558370-25-006746 20250331 Common Stock Shares Issued 20367574.0000 shares 0 us-gaap/2024 Class Of Stock= Common Class A;
0001558370-25-006746 20240630 Common Stock Shares Outstanding 20337574.0000 shares 0 us-gaap/2024 Class Of Stock= Common Class A;
0001558370-25-006746 20250331 Common Stock Shares Outstanding 20367574.0000 shares 0 us-gaap/2024 Class Of Stock= Common Class A;
0001558370-25-006746 20250331 Common Stock Value Outstanding 4000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20240331 Comprehensive Income Net Of Tax 8405000.0000 USD 1 us-gaap/2024 Equity Components= Retained Earnings;
0001558370-25-006746 20240331 Cost Of Goods And Services Sold 183623000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20240331 Deferred Income Taxes And Tax Credits -6806000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240331 Depreciation Depletion And Amortization 7695000.0000 USD 1 us-gaap/2024 Business Segments= Animal Health; Consolidation Items= Operating Segments;
0001558370-25-006746 20240331 Depreciation Depletion And Amortization 468000.0000 USD 1 us-gaap/2024 Consolidation Items= Corporate Non Segment;
0001558370-25-006746 20240331 Depreciation Depletion And Amortization 22392000.0000 USD 3 us-gaap/2024 Business Segments= Animal Health; Consolidation Items= Operating Segments;
0001558370-25-006746 20240331 Depreciation Depletion And Amortization 1387000.0000 USD 3 us-gaap/2024 Consolidation Items= Corporate Non Segment;
0001558370-25-006746 20250331 Depreciation Depletion And Amortization 277000.0000 USD 1 us-gaap/2024 Business Segments= Performance Products; Consolidation Items= Operating Segments;
0001558370-25-006746 20240331 Dividends Common Stock Cash 4860000.0000 USD 1 us-gaap/2024 Equity Components= Retained Earnings;
0001558370-25-006746 20241231 Dividends Common Stock Cash 4860000.0000 USD 1 us-gaap/2024 Equity Components= Retained Earnings;
0001558370-25-006746 20250331 Dividends Common Stock Cash 4865000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20250331 Earnings Per Share Basic 0.7700 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Foreign Currency Transaction Gain Loss Before Tax -6609000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240331 Foreign Currency Transaction Gain Loss Unrealized -4261000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240331 Foreign Employment Taxes 4202000.0000 USD 3 0001558370-25-006746
0001558370-25-006746 20240630 Goodwill 54557000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20240331 Increase Decrease In Accrued Liabilities And Other Operating Liabilities 2905000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Increase Decrease In Prepaid Deferred Expense And Other Assets 7712000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Loans Payable Current 16250000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20250331 Net Cash Provided By Used In Operating Activities 58852000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240630 Other Assets Noncurrent 78297000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20250331 Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Before Tax Parent -7983000.0000 USD 3 us-gaap/2024 Derivative Instrument Risk= Interest Rate Swap;
0001558370-25-006746 20240331 Other Comprehensive Income Loss Finalization Of Pension And Non Pension Postretirement Plan Valuation Before Tax 10674000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent -4389000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20240331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent 206000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Net Unamortized Gain Loss Arising During Period Before Tax 75000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20240331 Payments Of Dividends Common Stock 14581000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Payments To Acquire Short Term Investments 10000000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240331 Proceeds From Long Term Lines Of Credit 155000000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240331 Revenue From Contract With Customer Excluding Assessed Tax 263223000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20240331 Revenue From Contract With Customer Excluding Assessed Tax 33175000.0000 USD 1 us-gaap/2024 Geographical= E M E A;
0001558370-25-006746 20240331 Revenue From Contract With Customer Excluding Assessed Tax 53653000.0000 USD 1 us-gaap/2024 Geographical= Latin America And Canada;
0001558370-25-006746 20240331 Revenue From Contract With Customer Excluding Assessed Tax 121840000.0000 USD 3 us-gaap/2024 Product Or Service= Nutritional Specialties;
0001558370-25-006746 20250331 Revenue From Contract With Customer Excluding Assessed Tax 347825000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20250331 Revenue From Contract With Customer Excluding Assessed Tax 28222000.0000 USD 1 us-gaap/2024 Geographical= Asia Pacific;
0001558370-25-006746 20250331 Revenue From Contract With Customer Excluding Assessed Tax 258377000.0000 USD 1 us-gaap/2024 Product Or Service= Animal Health;
0001558370-25-006746 20250331 Revenue From Contract With Customer Excluding Assessed Tax 66774000.0000 USD 1 us-gaap/2024 Product Or Service= Mineral Nutrition;
0001558370-25-006746 20240331 Selling General And Administrative Expense 59676000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20240331 Share Based Compensation 296000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Share Based Compensation 538000.0000 USD 3 us-gaap/2024 Consolidation Items= Operating Segments;
0001558370-25-006746 20250331 Short Term Investments 0.0000 USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level3;
0001558370-25-006746 20230930 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -110856000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001558370-25-006746 20230930 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 4000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001558370-25-006746 20230930 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 248037000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001558370-25-006746 20231231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 270803000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20231231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 244450000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001558370-25-006746 20240930 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -123935000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001558370-25-006746 20250331 Weighted Average Number Of Shares Outstanding Basic 40520000.0000 shares 1 us-gaap/2024
0001558370-25-006746 20250331 Weighted Average Number Of Shares Outstanding Basic 40509000.0000 shares 3 us-gaap/2024
0001558370-25-006746 20240630 Accounts Receivable Net Current 169452000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20250331 Accounts Receivable Net Current 197518000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20240630 Assets 684407000.0000 USD 0 us-gaap/2024 Business Segments= Animal Health; Consolidation Items= Operating Segments;
0001558370-25-006746 20250331 Assets 1317260000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20230630 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 41281000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20240331 Comprehensive Income Net Of Tax -4389000.0000 USD 1 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001558370-25-006746 20240930 Comprehensive Income Net Of Tax 6567000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20240331 Depreciation Depletion And Amortization 601000.0000 USD 1 us-gaap/2024 Business Segments= Mineral Nutrition; Consolidation Items= Operating Segments;
0001558370-25-006746 20250331 Depreciation Depletion And Amortization 12170000.0000 USD 1 us-gaap/2024 Consolidation Items= Operating Segments;
0001558370-25-006746 20250331 Depreciation Depletion And Amortization 33194000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20241231 Dividends Common Stock Cash 4860000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20250331 Dividends Common Stock Cash 4865000.0000 USD 1 us-gaap/2024 Equity Components= Retained Earnings;
0001558370-25-006746 20240331 Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents -2583000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest 12922000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20250331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest 29688000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20250331 Increase Decrease In Accounts Receivable 29251000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Interest Income Expense Nonoperating Net -9355000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20250331 Inventory Net 448390000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20250331 Net Income Loss 20880000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20250331 Other Assets Current 59756000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20240331 Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Before Tax Parent -1793000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20240331 Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Before Tax Parent -875000.0000 USD 1 us-gaap/2024 Derivative Instrument Risk= Foreign Exchange Option;
0001558370-25-006746 20240331 Pension Expense Reversal Of Expense Noncash 10674000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Proceeds From Maturities Prepayments And Calls Of Shortterm Investments 44000000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240331 Repayments Of Long Term Lines Of Credit 131000000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Repayments Of Long Term Lines Of Credit 563000000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240331 Repayments Of Other Long Term Debt 15315000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240331 Revenue From Contract With Customer Excluding Assessed Tax 32923000.0000 USD 1 us-gaap/2024 Product Or Service= Vaccines;
0001558370-25-006746 20240331 Revenue From Contract With Customer Excluding Assessed Tax 744515000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240331 Revenue From Contract With Customer Excluding Assessed Tax 46321000.0000 USD 3 us-gaap/2024 Geographical= Asia Pacific;
0001558370-25-006746 20240331 Revenue From Contract With Customer Excluding Assessed Tax 431083000.0000 USD 3 us-gaap/2024 Geographical= U S;
0001558370-25-006746 20250331 Revenue From Contract With Customer Excluding Assessed Tax 33382000.0000 USD 1 us-gaap/2024 Product Or Service= Vaccines;
0001558370-25-006746 20250331 Revenue From Contract With Customer Excluding Assessed Tax 917518000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Revenue From Contract With Customer Excluding Assessed Tax 189086000.0000 USD 3 us-gaap/2024 Business Segments= Mineral Nutrition;
0001558370-25-006746 20250331 Revenue From Contract With Customer Excluding Assessed Tax 537930000.0000 USD 3 us-gaap/2024 Geographical= U S;
0001558370-25-006746 20250331 Revenue From Contract With Customer Excluding Assessed Tax 58114000.0000 USD 3 us-gaap/2024 Product Or Service= Performance Products;
0001558370-25-006746 20240930 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 136457000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001558370-25-006746 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -114004000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001558370-25-006746 20240331 Acquisition Related Items 1033000.0000 USD 3 0001558370-25-006746
0001558370-25-006746 20240331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 135000.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001558370-25-006746 20250331 Amortization Of Financing Costs 572000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20250331 Asset Impairment Charges 5300000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20250331 Asset Impairment Charges 5328000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Asset Impairment Charges 1500000.0000 USD 3 us-gaap/2024 Income Statement Location= Selling General And Administrative Expenses;
0001558370-25-006746 20250331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect -10259000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240930 Common Stock Dividends Per Share Declared 0.1200 USD 1 us-gaap/2024
0001558370-25-006746 20250331 Common Stock Shares Authorized 30000000.0000 shares 0 us-gaap/2024 Class Of Stock= Common Class B;
0001558370-25-006746 20230630 Common Stock Shares Issued 40503608.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0001558370-25-006746 20240630 Common Stock Shares Issued 20166034.0000 shares 0 us-gaap/2024 Class Of Stock= Common Class B;
0001558370-25-006746 20240630 Common Stock Value Outstanding 4000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20240331 Comprehensive Income Net Of Tax 1870000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Earnings Per Share Diluted 0.5100 USD 1 us-gaap/2024
0001558370-25-006746 20250331 Goodwill 54570000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20250331 Interest Income Expense Nonoperating Net -25992000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240630 Liabilities And Stockholders Equity 982184000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20250331 Liabilities And Stockholders Equity 1317260000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20240630 Liabilities Current 204148000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20250331 Liabilities Current 266481000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20250331 Long Term Loans Payable 619157000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20250331 Net Cash Provided By Used In Financing Activities 214900000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Net Cash Provided By Used In Investing Activities -281654000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Operating Income Loss 76747000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent -1868000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240331 Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Before Tax Parent -918000.0000 USD 1 us-gaap/2024 Derivative Instrument Risk= Interest Rate Swap;
0001558370-25-006746 20240331 Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Net Unamortized Gain Loss Arising During Period Before Tax 92000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20250331 Other Comprehensive Income Loss Tax Portion Attributable To Parent1 -1300000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20240331 Payments To Acquire Businesses Net Of Cash Acquired 3282000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240331 Payments To Acquire Productive Assets 28166000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Preferred Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0001558370-25-006746 20250331 Preferred Stock Shares Issued 0.0000 shares 0 us-gaap/2024
0001558370-25-006746 20240630 Preferred Stock Value Outstanding USD 0 us-gaap/2024
0001558370-25-006746 20240331 Proceeds From Maturities Prepayments And Calls Of Shortterm Investments 57000000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Repayments Of Other Long Term Debt 320953000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240331 Revenue From Contract With Customer Excluding Assessed Tax 514967000.0000 USD 3 us-gaap/2024 Business Segments= Animal Health;
0001558370-25-006746 20250331 Revenue From Contract With Customer Excluding Assessed Tax 670318000.0000 USD 3 us-gaap/2024 Business Segments= Animal Health;
0001558370-25-006746 20250331 Short Term Investments 0.0000 USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level2;
0001558370-25-006746 20230630 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 282509000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20230630 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -114210000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001558370-25-006746 20230630 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 4000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001558370-25-006746 20240930 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 4000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001558370-25-006746 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 4000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001558370-25-006746 20250331 Stock Issued During Period Shares Share Based Compensation Gross 30000.0000 shares 1 us-gaap/2024 Equity Components= Common Stock;
0001558370-25-006746 20240630 Accrued Liabilities And Other Liabilities Current 88786000.0000 USD 0 0001558370-25-006746
0001558370-25-006746 20240630 Accumulated Other Comprehensive Income Loss Net Of Tax -123527000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20250331 Acquisition Related Items 3342000.0000 USD 3 0001558370-25-006746
0001558370-25-006746 20250331 Additional Paid In Capital Common Stock 136816000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20240331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 135000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20240930 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 179000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20250331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 179000.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001558370-25-006746 20240331 Amortization Of Financing Costs 780000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240630 Assets 50862000.0000 USD 0 us-gaap/2024 Business Segments= Performance Products; Consolidation Items= Operating Segments;
0001558370-25-006746 20250331 Assets 1172568000.0000 USD 0 us-gaap/2024 Consolidation Items= Operating Segments;
0001558370-25-006746 20240630 Cash And Cash Equivalents At Carrying Value 70613000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20240331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 50225000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20250331 Commitments And Contingencies USD 0 us-gaap/2024
0001558370-25-006746 20231231 Common Stock Dividends Per Share Declared 0.1200 USD 1 us-gaap/2024
0001558370-25-006746 20250331 Revenue From Contract With Customer Excluding Assessed Tax 22674000.0000 USD 1 us-gaap/2024 Business Segments= Performance Products;
0001558370-25-006746 20241231 Common Stock Dividends Per Share Declared 0.1200 USD 1 us-gaap/2024
0001558370-25-006746 20240630 Common Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024 Class Of Stock= Common Class A;
0001558370-25-006746 20240930 Common Stock Shares Issued 40503608.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0001558370-25-006746 20241231 Common Stock Shares Issued 40503608.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0001558370-25-006746 20250331 Common Stock Shares Issued 40533608.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0001558370-25-006746 20230930 Comprehensive Income Net Of Tax 3354000.0000 USD 1 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001558370-25-006746 20240930 Comprehensive Income Net Of Tax 6975000.0000 USD 1 us-gaap/2024 Equity Components= Retained Earnings;
0001558370-25-006746 20241231 Comprehensive Income Net Of Tax 3185000.0000 USD 1 us-gaap/2024 Equity Components= Retained Earnings;
0001558370-25-006746 20250331 Depreciation Depletion And Amortization 446000.0000 USD 1 us-gaap/2024 Consolidation Items= Corporate Non Segment;
0001558370-25-006746 20250331 Depreciation Depletion And Amortization 29318000.0000 USD 3 us-gaap/2024 Business Segments= Animal Health; Consolidation Items= Operating Segments;
0001558370-25-006746 20250331 Depreciation Depletion And Amortization 31775000.0000 USD 3 us-gaap/2024 Consolidation Items= Operating Segments;
0001558370-25-006746 20240930 Dividends Common Stock Cash 4860000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20250331 Earnings Per Share Basic 0.5200 USD 1 us-gaap/2024
0001558370-25-006746 20240331 Foreign Currency Transaction Gain Loss Before Tax -16593000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240331 Gross Profit 225942000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Income Tax Expense Benefit 8808000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20240331 Increase Decrease In Accounts Payable 8099000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240331 Increase Decrease In Accounts Receivable -3045000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240331 Interest Income Expense Nonoperating Net -4575000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20240630 Loans Payable Current 29795000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20240630 Long Term Loans Payable 282289000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20240331 Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Before Tax Parent -8442000.0000 USD 3 us-gaap/2024 Derivative Instrument Risk= Interest Rate Swap;
0001558370-25-006746 20250331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent 2996000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20250331 Other Liabilities Noncurrent 73630000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20240331 Payments For Proceeds From Other Investing Activities -888000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240630 Property Plant And Equipment Net 203300000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20250331 Property Plant And Equipment Net 336093000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20240630 Retained Earnings Accumulated Deficit 243886000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20240331 Revenue From Contract With Customer Excluding Assessed Tax 17662000.0000 USD 1 us-gaap/2024 Business Segments= Performance Products;
0001558370-25-006746 20240331 Revenue From Contract With Customer Excluding Assessed Tax 40194000.0000 USD 1 us-gaap/2024 Product Or Service= Nutritional Specialties;
0001558370-25-006746 20240331 Revenue From Contract With Customer Excluding Assessed Tax 181601000.0000 USD 3 us-gaap/2024 Product Or Service= Mineral Nutrition;
0001558370-25-006746 20250331 Revenue From Contract With Customer Excluding Assessed Tax 258377000.0000 USD 1 us-gaap/2024 Business Segments= Animal Health;
0001558370-25-006746 20250331 Revenue From Contract With Customer Excluding Assessed Tax 214578000.0000 USD 3 us-gaap/2024 Geographical= Latin America And Canada;
0001558370-25-006746 20250331 Revenue From Contract With Customer Excluding Assessed Tax 670318000.0000 USD 3 us-gaap/2024 Product Or Service= Animal Health;
0001558370-25-006746 20250331 Revenue From Contract With Customer Excluding Assessed Tax 131908000.0000 USD 3 us-gaap/2024 Product Or Service= Nutritional Specialties;
0001558370-25-006746 20250331 Selling General And Administrative Expense 71053000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20240331 Share Based Compensation 296000.0000 USD 3 us-gaap/2024 Consolidation Items= Operating Segments;
0001558370-25-006746 20230930 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 273069000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20240930 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 246001000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001558370-25-006746 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 265992000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 136816000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001558370-25-006746 20240331 Weighted Average Number Of Shares Outstanding Basic 40504000.0000 shares 3 us-gaap/2024
0001558370-25-006746 20240630 Additional Paid In Capital Common Stock 136278000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20231231 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 80000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20241231 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 180000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20240331 Amortization Of Financing Costs 260000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20250331 Asset Impairment Charges 3800000.0000 USD 1 us-gaap/2024 Income Statement Location= Cost Of Sales;
0001558370-25-006746 20250331 Assets 1041878000.0000 USD 0 us-gaap/2024 Business Segments= Animal Health; Consolidation Items= Operating Segments;
0001558370-25-006746 20250331 Cash And Cash Equivalents At Carrying Value 60354000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20240331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect 8944000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240630 Common Stock Shares Authorized 30000000.0000 shares 0 us-gaap/2024 Class Of Stock= Common Class B;
0001558370-25-006746 20240331 Common Stock Shares Issued 40503608.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0001558370-25-006746 20240630 Common Stock Shares Issued 40503608.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0001558370-25-006746 20250331 Common Stock Shares Issued 20166034.0000 shares 0 us-gaap/2024 Class Of Stock= Common Class B;
0001558370-25-006746 20240630 Common Stock Shares Outstanding 20166034.0000 shares 0 us-gaap/2024 Class Of Stock= Common Class B;
0001558370-25-006746 20231231 Comprehensive Income Net Of Tax 1241000.0000 USD 1 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001558370-25-006746 20241231 Comprehensive Income Net Of Tax -10230000.0000 USD 1 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001558370-25-006746 20250331 Deferred Income Taxes And Tax Credits -13241000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240331 Depreciation Depletion And Amortization 8728000.0000 USD 1 us-gaap/2024 Consolidation Items= Operating Segments;
0001558370-25-006746 20250331 Depreciation Depletion And Amortization 12616000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20231231 Dividends Common Stock Cash 4861000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20240630 Finite Lived Intangible Assets Net 45033000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20250331 Foreign Currency Transaction Gain Loss Before Tax 5528000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20240331 Gross Profit 79600000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20250331 Gross Profit 289933000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Increase Decrease In Accrued Liabilities And Other Operating Liabilities 21043000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Increase Decrease In Inventories 38133000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240630 Inventory Net 265911000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20240331 Net Cash Provided By Used In Investing Activities -39083000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240331 Net Cash Provided By Used In Operating Activities 59165000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240331 Operating Income Loss 19924000.0000 USD 1 us-gaap/2024
0001558370-25-006746 20250331 Other Assets Noncurrent 112813000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20240331 Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent -2187000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240331 Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Before Tax Parent -8407000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Net Unamortized Gain Loss Arising During Period Before Tax 233000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Other Noncash Income Expense 1167000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20250331 Payments For Insurance Premium Financing Financing Activities 5185000.0000 USD 3 0001558370-25-006746
0001558370-25-006746 20250331 Payments Of Debt Issuance Costs 10377000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240630 Preferred Stock Par Or Stated Value Per Share 0.0001 USD 0 us-gaap/2024
0001558370-25-006746 20240630 Preferred Stock Shares Issued 0.0000 shares 0 us-gaap/2024
0001558370-25-006746 20250331 Preferred Stock Value Outstanding USD 0 us-gaap/2024
0001558370-25-006746 20250331 Proceeds From Long Term Lines Of Credit 479000000.0000 USD 3 us-gaap/2024
0001558370-25-006746 20240630 Short Term Investments 44000000.0000 USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level1;
0001558370-25-006746 20250331 Retained Earnings Accumulated Deficit 260341000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20240331 Revenue From Contract With Customer Excluding Assessed Tax 181333000.0000 USD 1 us-gaap/2024 Business Segments= Animal Health;
0001558370-25-006746 20240331 Revenue From Contract With Customer Excluding Assessed Tax 64228000.0000 USD 1 us-gaap/2024 Business Segments= Mineral Nutrition;
0001558370-25-006746 20240331 Revenue From Contract With Customer Excluding Assessed Tax 514967000.0000 USD 3 us-gaap/2024 Product Or Service= Animal Health;
0001558370-25-006746 20240331 Revenue From Contract With Customer Excluding Assessed Tax 88866000.0000 USD 3 us-gaap/2024 Product Or Service= Vaccines;
0001558370-25-006746 20250331 Revenue From Contract With Customer Excluding Assessed Tax 66774000.0000 USD 1 us-gaap/2024 Business Segments= Mineral Nutrition;
0001558370-25-006746 20250331 Revenue From Contract With Customer Excluding Assessed Tax 38910000.0000 USD 1 us-gaap/2024 Geographical= E M E A;
0001558370-25-006746 20250331 Revenue From Contract With Customer Excluding Assessed Tax 43350000.0000 USD 1 us-gaap/2024 Product Or Service= Nutritional Specialties;
0001558370-25-006746 20250331 Revenue From Contract With Customer Excluding Assessed Tax 62386000.0000 USD 3 us-gaap/2024 Geographical= Asia Pacific;
0001558370-25-006746 20240331 Share Based Compensation 135000.0000 USD 1 us-gaap/2024 Consolidation Items= Operating Segments;
0001558370-25-006746 20240630 Short Term Investments 0.0000 USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level2;
0001558370-25-006746 20230630 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 135803000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001558370-25-006746 20230930 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 135884000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001558370-25-006746 20231231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -109615000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001558370-25-006746 20231231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 135964000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0001558370-25-006746 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 4000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001558370-25-006746 20240630 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 4000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001558370-25-006746 20241231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 246802000.0000 USD 0 us-gaap/2024
0001558370-25-006746 20241231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -134165000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001558370-25-006746 20241231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 244326000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001558370-25-006746 20240331 Weighted Average Number Of Shares Outstanding Basic 40504000.0000 shares 1 us-gaap/2024

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
tag The unique identifier (name) for a tag in a specific taxonomy release.
version For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined.
ddate The end date for the data value, rounded to the nearest month end.
qtrs The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value.
uom The unit of measure for the value.
segments Tags used to represent axis and member reporting.
coreg If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity.
value The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point.
footnote The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank.

Tags

tag version custom abstract datatype iord crdr tlabel doc
Increase Decrease In Accounts Receivable us-gaap/2024 0 0 monetary D C Increase (Decrease) in Accounts Receivable The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
Assets Current us-gaap/2024 0 0 monetary I D Assets, Current Amount of asset recognized for present right to economic benefit, classified as current.
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 0 0 monetary I D Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Increase Decrease In Other Noncurrent Assets us-gaap/2024 0 0 monetary D C Increase (Decrease) in Other Noncurrent Assets Amount of increase (decrease) in noncurrent assets classified as other.
Revenue From Contract With Customer Excluding Assessed Tax us-gaap/2024 0 0 monetary D C Revenue from Contract with Customer, Excluding Assessed Tax Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
Comprehensive Income Net Of Tax us-gaap/2024 0 0 monetary D C Comprehensive Income (Loss), Net of Tax, Attributable to Parent Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
Other Comprehensive Income Loss Tax Portion Attributable To Parent1 us-gaap/2024 0 0 monetary D D Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.
Payments To Acquire Businesses Net Of Cash Acquired us-gaap/2024 0 0 monetary D C Payments to Acquire Businesses, Net of Cash Acquired The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.
Stockholders Equity Including Portion Attributable To Noncontrolling Interest us-gaap/2024 0 0 monetary I C Equity, Including Portion Attributable to Noncontrolling Interest Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest us-gaap/2024 0 0 monetary D C Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Interest Income Expense Nonoperating Net us-gaap/2024 0 0 monetary D C Interest Income (Expense), Nonoperating Amount of interest income (expense) classified as nonoperating.
Liabilities us-gaap/2024 0 0 monetary I C Liabilities Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.
Liabilities And Stockholders Equity us-gaap/2024 0 0 monetary I C Liabilities and Equity Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
Long Term Loans Payable us-gaap/2024 0 0 monetary I C Loans Payable, Noncurrent Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.
Other Comprehensive Income Loss Finalization Of Pension And Non Pension Postretirement Plan Valuation Before Tax us-gaap/2024 0 0 monetary D C Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement and Curtailment Gain (Loss), before Tax Amount, before tax, of increase (decrease) to other comprehensive income from settlement and curtailment gain (loss) of defined benefit plan.
Payments To Acquire Productive Assets us-gaap/2024 0 0 monetary D C Payments to Acquire Productive Assets The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.
Retained Earnings Accumulated Deficit us-gaap/2024 0 0 monetary I C Retained Earnings (Accumulated Deficit) Amount of accumulated undistributed earnings (deficit).
Short Term Investments us-gaap/2024 0 0 monetary I D Short-Term Investments Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.
Accounts Receivable Net Current us-gaap/2024 0 0 monetary I D Accounts Receivable, after Allowance for Credit Loss, Current Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Asset Impairment Charges us-gaap/2024 0 0 monetary D D Asset Impairment Charges Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.
Common Stock Dividends Per Share Declared us-gaap/2024 0 0 perShare D Common Stock, Dividends, Per Share, Declared Aggregate dividends declared during the period for each share of common stock outstanding.
Common Stock Par Or Stated Value Per Share us-gaap/2024 0 0 perShare I Common Stock, Par or Stated Value Per Share Face amount or stated value per share of common stock.
Common Stock Shares Outstanding us-gaap/2024 0 0 shares I Common Stock, Shares, Outstanding Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
Income Tax Expense Benefit us-gaap/2024 0 0 monetary D D Income Tax Expense (Benefit) Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Net Income Loss us-gaap/2024 0 0 monetary D C Net Income (Loss) Attributable to Parent The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Before Tax Parent us-gaap/2024 0 0 monetary D C Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax, Parent Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness, attributable to parent.
Payments Of Debt Issuance Costs us-gaap/2024 0 0 monetary D C Payments of Debt Issuance Costs The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.
Pension Expense Reversal Of Expense Noncash us-gaap/2024 0 0 monetary D D Pension Expense (Reversal of Expense), Noncash Amount of noncash expense (reversal of expense) for pension benefits. Excludes other postretirement benefits.
Preferred Stock Value Outstanding us-gaap/2024 0 0 monetary I C Preferred Stock, Value, Outstanding Value of nonredeemable preferred shares and preferred shares redeemable solely at option of issuer, held by shareholders. Excludes preferred shares repurchased and held as treasury shares.
Stockholders Equity us-gaap/2024 0 0 monetary I C Equity, Attributable to Parent Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
Weighted Average Number Of Diluted Shares Outstanding us-gaap/2024 0 0 shares D Weighted Average Number of Shares Outstanding, Diluted The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Proceeds From Insurance Premium Financing Financing Activities 0001558370-25-006746 1 0 monetary D D Proceeds from Insurance Premium Financing, Financing Activities Proceeds from Insurance Premium Financing, Financing Activities
Accumulated Other Comprehensive Income Loss Net Of Tax us-gaap/2024 0 0 monetary I C Accumulated Other Comprehensive Income (Loss), Net of Tax Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.
Payments For Insurance Premium Financing Financing Activities 0001558370-25-006746 1 0 monetary D C Payments for Insurance Premium Financing, Financing Activities Payments for Insurance Premium Financing, Financing Activities
Assets us-gaap/2024 0 0 monetary I D Assets Amount of asset recognized for present right to economic benefit.
Common Stock Shares Issued us-gaap/2024 0 0 shares I Common Stock, Shares, Issued Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
Cost Of Goods And Services Sold us-gaap/2024 0 0 monetary D D Cost of Goods and Services Sold The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
Dividends Common Stock Cash us-gaap/2024 0 0 monetary D D Dividends, Common Stock, Cash Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.
Earnings Per Share Diluted us-gaap/2024 0 0 perShare D Earnings Per Share, Diluted The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 0 0 monetary D D Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Other Assets Noncurrent us-gaap/2024 0 0 monetary I D Other Assets, Noncurrent Amount of noncurrent assets classified as other.
Foreign Currency Transaction Gain Loss Unrealized us-gaap/2024 0 0 monetary D C Unrealized Gain (Loss), Foreign Currency Transaction, before Tax Amount, before tax, of unrealized gain (loss) from foreign currency transaction.
Gross Profit us-gaap/2024 0 0 monetary D C Gross Profit Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
Payments For Proceeds From Other Investing Activities us-gaap/2024 0 0 monetary D C Payments for (Proceeds from) Other Investing Activities Amount of cash (inflow) outflow from investing activities classified as other.
Repayments Of Other Long Term Debt us-gaap/2024 0 0 monetary D C Repayments of Other Long-Term Debt Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.
Acquisition Related Items 0001558370-25-006746 1 0 monetary D D Acquisition Related Items Represents amount of business acquisition related items.
Depreciation Depletion And Amortization us-gaap/2024 0 0 monetary D D Depreciation, Depletion and Amortization The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
Foreign Employment Taxes 0001558370-25-006746 1 0 monetary D D Foreign Employment Taxes Foreign Employment Taxes
Liabilities Current us-gaap/2024 0 0 monetary I C Liabilities, Current Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent us-gaap/2024 0 0 monetary D C Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Portion Attributable to Parent Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, on foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.
Preferred Stock Shares Issued us-gaap/2024 0 0 shares I Preferred Stock, Shares Issued Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.
Proceeds From Maturities Prepayments And Calls Of Shortterm Investments us-gaap/2024 0 0 monetary D D Proceeds from Maturities, Prepayments and Calls of Short-Term Investments The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.
Selling General And Administrative Expense us-gaap/2024 0 0 monetary D D Selling, General and Administrative Expense The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
Share Based Compensation us-gaap/2024 0 0 monetary D D Share-Based Payment Arrangement, Noncash Expense Amount of noncash expense for share-based payment arrangement.
Foreign Currency Transaction Gain Loss Before Tax us-gaap/2024 0 0 monetary D C Gain (Loss), Foreign Currency Transaction, before Tax Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.
Cash And Cash Equivalents At Carrying Value us-gaap/2024 0 0 monetary I D Cash and Cash Equivalents, at Carrying Value Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
Amortization Of Financing Costs us-gaap/2024 0 0 monetary D D Amortization of Debt Issuance Costs Amount of amortization expense attributable to debt issuance costs.
Increase Decrease In Inventories us-gaap/2024 0 0 monetary D C Increase (Decrease) in Inventories The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
Increase Decrease In Prepaid Deferred Expense And Other Assets us-gaap/2024 0 0 monetary D C Increase (Decrease) in Prepaid Expense and Other Assets Amount of increase (decrease) in prepaid expenses, and assets classified as other.
Loans Payable Current us-gaap/2024 0 0 monetary I C Loans Payable, Current Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.
Long Term Line Of Credit us-gaap/2024 0 0 monetary I C Long-Term Line of Credit, Noncurrent The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.
Other Noncash Income Expense us-gaap/2024 0 0 monetary D C Other Noncash Income (Expense) Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.
Profit Loss us-gaap/2024 0 0 monetary D C Net Income (Loss), Including Portion Attributable to Noncontrolling Interest The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
Stock Issued During Period Shares Share Based Compensation Gross us-gaap/2024 0 0 shares D Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).
Accrued Liabilities And Other Liabilities Current 0001558370-25-006746 1 0 monetary I C Accrued Liabilities and Other Liabilities, Current Accrued Liabilities and Other Liabilities, Current
Finite Lived Intangible Assets Net us-gaap/2024 0 0 monetary I D Finite-Lived Intangible Assets, Net Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
Goodwill us-gaap/2024 0 0 monetary I D Goodwill Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.
Increase Decrease In Accrued Liabilities And Other Operating Liabilities us-gaap/2024 0 0 monetary D D Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Amount of increase (decrease) in accrued expenses, and obligations classified as other.
Net Cash Provided By Used In Operating Activities us-gaap/2024 0 0 monetary D Net Cash Provided by (Used in) Operating Activities Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
Operating Income Loss us-gaap/2024 0 0 monetary D C Operating Income (Loss) The net result for the period of deducting operating expenses from operating revenues.
Other Assets Current us-gaap/2024 0 0 monetary I D Other Assets, Current Amount of current assets classified as other.
Other Liabilities Noncurrent us-gaap/2024 0 0 monetary I C Other Liabilities, Noncurrent Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
Proceeds From Issuance Of Other Long Term Debt us-gaap/2024 0 0 monetary D D Proceeds from Issuance of Other Long-Term Debt Amount of cash inflow from issuance of long-term debt classified as other.
Proceeds From Long Term Lines Of Credit us-gaap/2024 0 0 monetary D D Proceeds from Long-Term Lines of Credit The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.
Inventory Net us-gaap/2024 0 0 monetary I D Inventory, Net Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent us-gaap/2024 0 0 monetary D C Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Amount after tax of other comprehensive income (loss) attributable to parent entity.
Accounts Payable Current us-gaap/2024 0 0 monetary I C Accounts Payable, Current Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Additional Paid In Capital Common Stock us-gaap/2024 0 0 monetary I C Additional Paid in Capital, Common Stock Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect us-gaap/2024 0 0 monetary D D Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Commitments And Contingencies us-gaap/2024 0 0 monetary I C Commitments and Contingencies Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
Common Stock Shares Authorized us-gaap/2024 0 0 shares I Common Stock, Shares Authorized The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
Increase Decrease In Accounts Payable us-gaap/2024 0 0 monetary D D Increase (Decrease) in Accounts Payable The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
Net Cash Provided By Used In Financing Activities us-gaap/2024 0 0 monetary D D Net Cash Provided by (Used in) Financing Activities Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Preferred Stock Par Or Stated Value Per Share us-gaap/2024 0 0 perShare I Preferred Stock, Par or Stated Value Per Share Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value us-gaap/2024 0 0 monetary D C APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.
Common Stock Value Outstanding us-gaap/2024 0 0 monetary I C Common Stock, Value, Outstanding Value of common shares held by shareholders. Excludes common shares repurchased and held as treasury shares.
Deferred Income Taxes And Tax Credits us-gaap/2024 0 0 monetary D D Deferred Income Taxes and Tax Credits Amount of deferred income tax expense (benefit) and income tax credits.
Earnings Per Share Basic us-gaap/2024 0 0 perShare D Earnings Per Share, Basic The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
Net Cash Provided By Used In Investing Activities us-gaap/2024 0 0 monetary D D Net Cash Provided by (Used in) Investing Activities Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Net Unamortized Gain Loss Arising During Period Before Tax us-gaap/2024 0 0 monetary D C Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.
Preferred Stock Shares Authorized us-gaap/2024 0 0 shares I Preferred Stock, Shares Authorized The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
Preferred Stock Shares Outstanding us-gaap/2024 0 0 shares I Preferred Stock, Shares Outstanding Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
Payments Of Dividends Common Stock us-gaap/2024 0 0 monetary D C Payments of Ordinary Dividends, Common Stock Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.
Payments To Acquire Short Term Investments us-gaap/2024 0 0 monetary D C Payments to Acquire Short-Term Investments The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.
Property Plant And Equipment Net us-gaap/2024 0 0 monetary I D Property, Plant and Equipment, Net Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
Repayments Of Long Term Lines Of Credit us-gaap/2024 0 0 monetary D C Repayments of Long-Term Lines of Credit The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.
Weighted Average Number Of Shares Outstanding Basic us-gaap/2024 0 0 shares D Weighted Average Number of Shares Outstanding, Basic Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

Description
Field Name Field Description
tag The unique identifier (name) for a tag in a specific taxonomy release.
version For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined.
custom 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns.
abstract 1 if the tag is not used to represent a numeric fact.
datatype If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag.
iord If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration.
crdr If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL.
tlabel If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here.
doc The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL.

Presentation of Statements

adsh report line stmt inpth rfile tag version plabel negating
0001558370-25-006746 2 10 IS 0 H Income Tax Expense Benefit us-gaap/2024 Provision for income taxes 0
0001558370-25-006746 2 2 IS 0 H Revenue From Contract With Customer Excluding Assessed Tax us-gaap/2024 Net sales 0
0001558370-25-006746 2 3 IS 0 H Cost Of Goods And Services Sold us-gaap/2024 Cost of goods sold 1
0001558370-25-006746 2 4 IS 0 H Gross Profit us-gaap/2024 Gross profit 0
0001558370-25-006746 2 5 IS 0 H Selling General And Administrative Expense us-gaap/2024 Selling, general and administrative expenses 0
0001558370-25-006746 2 6 IS 0 H Operating Income Loss us-gaap/2024 Operating income 0
0001558370-25-006746 2 7 IS 0 H Interest Income Expense Nonoperating Net us-gaap/2024 Interest expense, net 1
0001558370-25-006746 2 8 IS 0 H Foreign Currency Transaction Gain Loss Before Tax us-gaap/2024 Foreign currency (gains) losses, net 1
0001558370-25-006746 2 9 IS 0 H Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest us-gaap/2024 Income before income taxes 0
0001558370-25-006746 2 11 IS 0 H Net Income Loss us-gaap/2024 Net income 0
0001558370-25-006746 2 13 IS 0 H Earnings Per Share Basic us-gaap/2024 basic (in dollars per share) 0
0001558370-25-006746 2 14 IS 0 H Earnings Per Share Diluted us-gaap/2024 diluted (in dollars per share) 0
0001558370-25-006746 2 16 IS 0 H Weighted Average Number Of Shares Outstanding Basic us-gaap/2024 basic (in shares) 0
0001558370-25-006746 2 17 IS 0 H Weighted Average Number Of Diluted Shares Outstanding us-gaap/2024 diluted (in shares) 0
0001558370-25-006746 3 2 CI 0 H Net Income Loss us-gaap/2024 Net Income (Loss) 0
0001558370-25-006746 3 3 CI 0 H Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification Before Tax Parent us-gaap/2024 Change in fair value of derivative instruments 0
0001558370-25-006746 3 4 CI 0 H Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent us-gaap/2024 Foreign currency translation adjustment 0
0001558370-25-006746 3 5 CI 0 H Other Comprehensive Income Loss Finalization Of Pension And Non Pension Postretirement Plan Valuation Before Tax us-gaap/2024 Pension settlement recognition 0
0001558370-25-006746 3 6 CI 0 H Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Net Unamortized Gain Loss Arising During Period Before Tax us-gaap/2024 Unrecognized net pension gains 0
0001558370-25-006746 3 7 CI 0 H Other Comprehensive Income Loss Tax Portion Attributable To Parent1 us-gaap/2024 Benefit (provision) for income taxes 1
0001558370-25-006746 3 8 CI 0 H Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent us-gaap/2024 Other comprehensive income (loss) 0
0001558370-25-006746 3 9 CI 0 H Comprehensive Income Net Of Tax us-gaap/2024 Comprehensive income 0
0001558370-25-006746 4 2 BS 0 H Cash And Cash Equivalents At Carrying Value us-gaap/2024 Cash and cash equivalents 0
0001558370-25-006746 4 3 BS 0 H Short Term Investments us-gaap/2024 Short-term investments 0
0001558370-25-006746 4 4 BS 0 H Accounts Receivable Net Current us-gaap/2024 Accounts receivable, net 0
0001558370-25-006746 4 5 BS 0 H Inventory Net us-gaap/2024 Inventories, net 0
0001558370-25-006746 4 6 BS 0 H Other Assets Current us-gaap/2024 Other current assets 0
0001558370-25-006746 4 7 BS 0 H Assets Current us-gaap/2024 Total current assets 0
0001558370-25-006746 4 8 BS 0 H Property Plant And Equipment Net us-gaap/2024 Property, plant and equipment, net 0
0001558370-25-006746 4 9 BS 0 H Finite Lived Intangible Assets Net us-gaap/2024 Intangibles, net 0
0001558370-25-006746 4 10 BS 0 H Goodwill us-gaap/2024 Goodwill 0
0001558370-25-006746 4 11 BS 0 H Other Assets Noncurrent us-gaap/2024 Other assets 0
0001558370-25-006746 4 12 BS 0 H Assets us-gaap/2024 Total assets 0
0001558370-25-006746 4 14 BS 0 H Loans Payable Current us-gaap/2024 Current portion of long-term debt 0
0001558370-25-006746 4 15 BS 0 H Accounts Payable Current us-gaap/2024 Accounts payable 0
0001558370-25-006746 4 16 BS 0 H Accrued Liabilities And Other Liabilities Current 0001558370-25-006746 Accrued expenses and other current liabilities 0
0001558370-25-006746 4 17 BS 0 H Liabilities Current us-gaap/2024 Total current liabilities 0
0001558370-25-006746 4 18 BS 0 H Long Term Line Of Credit us-gaap/2024 Revolving credit facility 0
0001558370-25-006746 4 19 BS 0 H Long Term Loans Payable us-gaap/2024 Long-term debt 0
0001558370-25-006746 4 20 BS 0 H Other Liabilities Noncurrent us-gaap/2024 Other liabilities 0
0001558370-25-006746 4 21 BS 0 H Liabilities us-gaap/2024 Total liabilities 0
0001558370-25-006746 4 22 BS 0 H Commitments And Contingencies us-gaap/2024 Commitments and contingencies (Note 9) 0
0001558370-25-006746 4 23 BS 0 H Common Stock Value Outstanding us-gaap/2024 Common stock, par value $0.0001 per share; 300,000,000 Class A shares authorized, 20,367,574 and 20,337,574 shares issued and outstanding at March 31, 2025, and June 30, 2024, respectively; 30,000,000 Class B shares authorized, 20,166,034 shares issued and outstanding at March 31, 2025, and June 30, 2024 0
0001558370-25-006746 4 24 BS 0 H Preferred Stock Value Outstanding us-gaap/2024 Preferred stock, par value $0.0001 per share; 16,000,000 shares authorized, no shares issued and outstanding 0
0001558370-25-006746 4 25 BS 0 H Additional Paid In Capital Common Stock us-gaap/2024 Paid-in capital 0
0001558370-25-006746 4 26 BS 0 H Retained Earnings Accumulated Deficit us-gaap/2024 Retained earnings 0
0001558370-25-006746 4 27 BS 0 H Accumulated Other Comprehensive Income Loss Net Of Tax us-gaap/2024 Accumulated other comprehensive loss 0
0001558370-25-006746 4 28 BS 0 H Stockholders Equity us-gaap/2024 Total stockholders' equity 0
0001558370-25-006746 4 29 BS 0 H Liabilities And Stockholders Equity us-gaap/2024 Total liabilities and stockholders' equity 0
0001558370-25-006746 5 8 BS 1 H Common Stock Par Or Stated Value Per Share us-gaap/2024 Common stock, par value (in dollars per share) 0
0001558370-25-006746 5 9 BS 1 H Common Stock Shares Authorized us-gaap/2024 Common stock, shares authorized (in shares) 0
0001558370-25-006746 5 10 BS 1 H Common Stock Shares Issued us-gaap/2024 Common stock, shares issued (in shares) 0
0001558370-25-006746 5 11 BS 1 H Common Stock Shares Outstanding us-gaap/2024 Common stock, shares outstanding (in shares) 0
0001558370-25-006746 5 13 BS 1 H Preferred Stock Par Or Stated Value Per Share us-gaap/2024 Preferred stock, par value (in dollars per share) 0
0001558370-25-006746 5 14 BS 1 H Preferred Stock Shares Authorized us-gaap/2024 Preferred stock, shares authorized (in shares) 0
0001558370-25-006746 5 15 BS 1 H Preferred Stock Shares Issued us-gaap/2024 Preferred stock, shares issued (in shares) 0
0001558370-25-006746 5 16 BS 1 H Preferred Stock Shares Outstanding us-gaap/2024 Preferred stock, shares outstanding (in shares) 0
0001558370-25-006746 6 2 CF 0 H Profit Loss us-gaap/2024 Net income 0
0001558370-25-006746 6 4 CF 0 H Depreciation Depletion And Amortization us-gaap/2024 Depreciation and amortization 0
0001558370-25-006746 6 5 CF 0 H Amortization Of Financing Costs us-gaap/2024 Amortization of debt issuance costs 0
0001558370-25-006746 6 6 CF 0 H Deferred Income Taxes And Tax Credits us-gaap/2024 Deferred income taxes 0
0001558370-25-006746 6 7 CF 0 H Foreign Currency Transaction Gain Loss Unrealized us-gaap/2024 Foreign currency losses, net 1
0001558370-25-006746 6 8 CF 0 H Acquisition Related Items 0001558370-25-006746 Acquisition-related items 0
0001558370-25-006746 6 9 CF 0 H Asset Impairment Charges us-gaap/2024 Non-cash impairment charges 0
0001558370-25-006746 6 10 CF 0 H Pension Expense Reversal Of Expense Noncash us-gaap/2024 Pension settlement cost 0
0001558370-25-006746 6 11 CF 0 H Foreign Employment Taxes 0001558370-25-006746 Brazil employment taxes 0
0001558370-25-006746 6 12 CF 0 H Share Based Compensation us-gaap/2024 Stock-based compensation expense 0
0001558370-25-006746 6 13 CF 0 H Other Noncash Income Expense us-gaap/2024 Other 1
0001558370-25-006746 6 15 CF 0 H Increase Decrease In Accounts Receivable us-gaap/2024 Accounts receivable, net 1
0001558370-25-006746 6 16 CF 0 H Increase Decrease In Inventories us-gaap/2024 Inventories, net 1
0001558370-25-006746 6 17 CF 0 H Increase Decrease In Prepaid Deferred Expense And Other Assets us-gaap/2024 Other current assets 1
0001558370-25-006746 6 18 CF 0 H Increase Decrease In Other Noncurrent Assets us-gaap/2024 Other assets 1
0001558370-25-006746 6 19 CF 0 H Increase Decrease In Accounts Payable us-gaap/2024 Accounts payable 0
0001558370-25-006746 6 20 CF 0 H Increase Decrease In Accrued Liabilities And Other Operating Liabilities us-gaap/2024 Accrued expenses and other liabilities 0
0001558370-25-006746 6 21 CF 0 H Net Cash Provided By Used In Operating Activities us-gaap/2024 Net cash provided by operating activities 0
0001558370-25-006746 6 23 CF 0 H Payments To Acquire Short Term Investments us-gaap/2024 Purchases of short-term investments 1
0001558370-25-006746 6 24 CF 0 H Proceeds From Maturities Prepayments And Calls Of Shortterm Investments us-gaap/2024 Maturities of short-term investments 0
0001558370-25-006746 6 25 CF 0 H Payments To Acquire Productive Assets us-gaap/2024 Capital expenditures 1
0001558370-25-006746 6 26 CF 0 H Payments To Acquire Businesses Net Of Cash Acquired us-gaap/2024 Business acquisition, net of cash acquired 1
0001558370-25-006746 6 27 CF 0 H Payments For Proceeds From Other Investing Activities us-gaap/2024 Other, net 1
0001558370-25-006746 6 28 CF 0 H Net Cash Provided By Used In Investing Activities us-gaap/2024 Net cash used by investing activities 0
0001558370-25-006746 6 30 CF 0 H Proceeds From Long Term Lines Of Credit us-gaap/2024 Revolving credit facility borrowings 0
0001558370-25-006746 6 31 CF 0 H Repayments Of Long Term Lines Of Credit us-gaap/2024 Revolving credit facility repayments 1
0001558370-25-006746 6 32 CF 0 H Proceeds From Issuance Of Other Long Term Debt us-gaap/2024 Proceeds from long-term debt 0
0001558370-25-006746 6 33 CF 0 H Repayments Of Other Long Term Debt us-gaap/2024 Payments of long-term debt 1
0001558370-25-006746 6 34 CF 0 H Payments Of Debt Issuance Costs us-gaap/2024 Debt issuance costs 1
0001558370-25-006746 6 35 CF 0 H Proceeds From Insurance Premium Financing Financing Activities 0001558370-25-006746 Proceeds from insurance premium financing 0
0001558370-25-006746 6 36 CF 0 H Payments For Insurance Premium Financing Financing Activities 0001558370-25-006746 Payments of insurance premium financing 1
0001558370-25-006746 6 37 CF 0 H Payments Of Dividends Common Stock us-gaap/2024 Dividends paid 1
0001558370-25-006746 6 38 CF 0 H Net Cash Provided By Used In Financing Activities us-gaap/2024 Net cash provided (used) by financing activities 0
0001558370-25-006746 6 39 CF 0 H Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 Effect of exchange rate changes on cash 0
0001558370-25-006746 6 40 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect us-gaap/2024 Net (decrease) increase in cash and cash equivalents 0
0001558370-25-006746 6 41 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 Cash and cash equivalents at beginning of period 0
0001558370-25-006746 6 42 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 Cash and cash equivalents at end of period 0
0001558370-25-006746 7 11 EQ 0 H Stockholders Equity Including Portion Attributable To Noncontrolling Interest us-gaap/2024 Balance 0
0001558370-25-006746 7 12 EQ 0 H Common Stock Shares Issued us-gaap/2024 Balance (in shares) 0
0001558370-25-006746 7 13 EQ 0 H Comprehensive Income Net Of Tax us-gaap/2024 Comprehensive income (loss) 0
0001558370-25-006746 7 15 EQ 0 H Stock Issued During Period Shares Share Based Compensation Gross us-gaap/2024 Shares issued pursuant to stock incentive plan (in shares) 0
0001558370-25-006746 7 16 EQ 0 H Dividends Common Stock Cash us-gaap/2024 Dividends declared 1
0001558370-25-006746 7 17 EQ 0 H Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value us-gaap/2024 Stock-based compensation expense 0
0001558370-25-006746 7 18 EQ 0 H Stockholders Equity Including Portion Attributable To Noncontrolling Interest us-gaap/2024 Balance 0
0001558370-25-006746 7 19 EQ 0 H Common Stock Shares Issued us-gaap/2024 Balance (in shares) 0
0001558370-25-006746 8 2 EQ 1 H Common Stock Dividends Per Share Declared us-gaap/2024 Dividends declared (in dollars per share) 0

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
report Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site.
line Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived.
stmt The financial statement location to which the value of the “report” field pertains.
inpth Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700.
rfile The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file.
tag The tag chosen by the filer for this line item.
version The taxonomy identifier if the tag is a standard tag, otherwise adsh.
plabel The text presented on the line item, also known as a “preferred” label.
negating Flag to indicate whether the plabel is negating.